"You decide and we provide."
Cart 0

Two-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies

reutersCOMPANYNEWS companyNews

April 20 (Reuters) - Doctors have struggled for years to deliver medication effectively to the inner ear, but two companies are vying to be first to introduce new treatments which, if successful, could together chalk up some $800 million in peak sales.

Older Post Newer Post

Leave a comment

Please note, comments must be approved before they are published